DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Empagliflozin
Drug: Sodium Glucose Transporter 2 inhibitor
Drug: Dipeptidyl-peptidase 4 inhibitor
Drug: Glucagon-like peptide 1 agonist

Registration Number: NCT03807440

Lead Sponsor: Boehringer Ingelheim

Brief Summary: This is a non-interventional study using existing data including medical chart review.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 4083

Inclusion Criteria

Written informed consent prior to participation
Female and male patients age ≥ 18 years
Patients with T2D diagnosis
Patients who have been newly initiated (first ever use) with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December 2018 (study index date 1)
Patients have been naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) at study index date 1

Exclusion Criteria

Patients age < 18 years
Patients with diagnosis of other types of diabetes than T2D
Patients who do not provide written consent to the terms of the study

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Subjects with Diabetes Mellitus, Type 2	Sodium Glucose Transporter 2 inhibitor	-
Subjects with Diabetes Mellitus, Type 2	Dipeptidyl-peptidase 4 inhibitor	-
Subjects with Diabetes Mellitus, Type 2	Glucagon-like peptide 1 agonist	-
Subjects with Diabetes Mellitus, Type 2	Empagliflozin	-

Primary Outcome Measures

Name	Time	Method
Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of prescription of a respective modern Type 2 Diabetes (T2D) medication according to prescribing specialist is reported.
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant T2D medications at study index date 1 according to prescribing specialist is reported. The concomitant T2D medications reported are: * Metformin * Sulfonylurea * Acarbose * Pioglitazone * Insulin * Others
Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant cardiovascular disease (CVD) and/or chronic kidney disease (CKD) medication at study index date 1 according to prescribing specialist is reported. The reported concomitant CVD and/or chronic CKD medications are: * Antihypertensive angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) * Statins * Low dose aspirin * Beta blockers * Diuretics * Others
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of gender are: * Female * Male
Baseline Characteristic: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of race are: * Black * Non-black
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of gender are: * Female * Male
Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of race are: * Black * Non-black
Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.
Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of gender are: * Female * Male
Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).
Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of race are: * Black * Non-black
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.
Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	Clinical parameter relevant for Type 2 Diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.
Clinical Parameter Relevant for T2D: Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	Clinical parameter relevant for Type 2 Diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of percentage (%) of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of percentage of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.
Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of percentage of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.
10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.
Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.

Secondary Outcome Measures

Name	Time	Method
Number of Patients With Chronic Kidney Disease (CKD) by Physician's Assessment	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with chronic kidney disease (CKD) by physician's assessment (patients for whom CKD was reported as a comorbidity) is reported.
Number of Patients With Any Type of Cardiovascular Disease (CVD) and Without CVD According to Prescribing Specialist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with any type of cardiovascular disease (CVD) or without CVD according to prescribing specialist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of different types of cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The following types of cardiovascular diseases are reported: * Myocardial infarction * Cardiology intervention (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG)) * Ischemic heart disease * Congestive heart failure * Stroke * Peripheral arterial disease The categories reported for each type of cardiovascular disease are: * Yes * No * Unknown
Number of Patients in Each Category of the Different Types of Congestive Heart Failure (CHF) - Confirmed by Echocardiography	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of the different types of congestive heart failure (CHF) which was confirmed by echocardiography is reported. The reported categories of congestive heart failure confirmed by echocardiography are: * Yes * No * Unknown
Number of Patients With Chronic Kidney (CKD) (Patients for Whom CKD Was Reported as a Comorbidity) or Without CKD by Physician's Assessment According to Prescribing Specialist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with chronic kidney (CKD) and without CKD by physician's assessment according to prescribing specialist is reported.
Number of Patients With Chronic Kidney Disease (CKD) by eGFR and UACR Status According to Prescribing Specialist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with chronic kidney disease (CKD) by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status - according to prescribing specialist is reported.
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication From by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Number of Patients With Any Type of Cardiovascular Disease (CVD)	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with cardiovascular disease (CVD) is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Number of Patients With Documentation of Estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) Status	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with documentation of estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) status is reported.
Number of Patients With Chronic Kidney Disease (CKD) by Estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) Status	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with Chronic Kidney Disease (CKD) by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status is reported.
Number of Patients in Each Category of the Different Types of Cardiovascular Disease	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of the different types of cardiovascular disease is reported. The following types of cardiovascular diseases are reported: * Myocardial infarction * Cardiology intervention (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG)) * Ischemic heart disease * Congestive heart failure * Stroke * Peripheral arterial disease The categories reported for each type of cardiovascular disease are: * Yes * No * Unknown
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown
Number of Patients in Each Category of Congestive Heart Failure (CHF) Confirmed by Echocardiography According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of congestive heart failure (CHF) confirmed by echocardiography according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of family status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of employment status are: * Employed * Not employed * Unknown
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of employment status are: * Employed * Not employed * Unknown
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of employment status are: * Employed * Not employed * Unknown
Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).	Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of status of T2D medication are: * Discontinued * Continued
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).	Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of status of T2D medication are: * Discontinued * Continued
Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.
Number of Patients With Chronic Kidney (CKD) or Without CKD by Physician's Assessment According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with chronic kidney (CKD) (patients for whom CKD was reported as a comorbidity) or without CKD by physician's assessment according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.
Number of Patients With Chronic Kidney (CKD) and Without CKD by eGFR and UACR Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients with chronic kidney (CKD) (patients for whom CKD was reported as a comorbidity) and without CKD by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.
Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of employment status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of employment status are: * Employed * Not employed * Unknown
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown
Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 1 (i.e. between September 2018 and December 2018).	Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).	Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of status of T2D medication are: * Discontinued * Continued
Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).	Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of status of T2D medication are: * Discontinued * Continued
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication by Country	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).	Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication by country is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).	Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).	Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).	Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).	Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other
Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist	At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).	Number of patients for each type of physician specialties involved in decision for T2D therapy discontinuation according to prescribing specialist is reported.
Time to Discontinuation of Type 2 Diabetes (T2D) Treatment According to Study Medication	From date of first prescription (study index date 1) to stop date of initial type 2 diabetes (T2D)) medication (documented at index date 2), up to 14 months..	Time to discontinuation of type 2 diabetes (T2D) treatment according to study medication is reported. Time to discontinuation of T2D medication was estimated by Kaplan-Meier analysis. Patients who did not discontinue study medication at study index date 2 were censored.

Trial Locations

Locations (177): Penza regional clinical hospital named after N.N. Burdenko, Center Nr.: 70095
🇷🇺
Penza, Russian Federation
MC "Diamedical 2013" OOD, Center Nr.: 35902
🇧🇬
Dimitrovgrad, Bulgaria
"Medical Center-Razgrad"OOD, Center Nr.: 35910
🇧🇬
Razgrad, Bulgaria
DCC 1 - Russe EOOD, Center Nr.: 35905
🇧🇬
Russe, Bulgaria
MBAL "Hadzhi Dimitar" OOD, Center Nr.: 35915
🇧🇬
Sliven, Bulgaria
MC Polimed AD, Center Nr.: 35907
🇧🇬
Sofia, Bulgaria
MC Gina - LZ SIMP EOOD, Center Nr.: 35918
🇧🇬
Sofia, Bulgaria
Poradnia Cukrzycowa SP ZOZ w Lesku, Center Nr.: 48024
🇵🇱
Lesko, Poland
Lumed Sp. z o.o., Center Nr.: 48032
🇵🇱
Lubaczów, Poland
DIABETA-CARE Sp.z o.o., Center Nr.: 48008
🇵🇱
Lubin, Poland
MED-ART Sp. z o.o., Center Nr.: 48052
🇵🇱
Orzesze, Poland
Prywatny Gabinet Lekarski azuka, Center Nr.: 48026
🇵🇱
Parczew, Poland
Powiatowy Szpital Specjalistyczny w Stalowej Woli, Center Nr.: 48056
🇵🇱
Stalowa Wola, Poland
Prywatny Gabinet Lekarski dr n. med. Piotr Gryglas, Center Nr.: 48059
🇵🇱
Warszawa, Poland
Poradnia Diabetologiczna Szpitala Powiatowego w Wicborku, Center Nr.: 48003
🇵🇱
Wicbork, Poland
Wojewódzka Poradnia dla Chorych na Cukrzyc, Center Nr.: 48025
🇵🇱
Zabrze, Poland
Poradnia Diabetologiczna Dr. mudziska, Center Nr.: 48013
🇵🇱
Nako Nad Noteci, Poland
Alfa Specjalistyczne Gabinety Lekarskie Ewa Moroz, Center Nr.: 48007
🇵🇱
Nowy Scz, Poland
Poradnia Diabetologiczna SPZZOZ w Wyszkowie, Center Nr.: 48067
🇵🇱
Wyszków, Poland
Cardiomed, Center Nr.: 48019
🇵🇱
Zielona Góra, Poland
Central city hospital, Center Nr.: 70073
🇷🇺
Batajsk, Russian Federation
Practice Zdzislaw Wranka, Center Nr.: 42072
🇨🇿
Karviná-Hranice, Czechia
Dr. Konená, Center Nr.: 42036
🇨🇿
Karviná - Staré Msto, Czechia
MUDr.Michala Pelikánová s.r.o., Center Nr.: 42055
🇨🇿
Praha 4, Czechia
Practice MUDr. Gita Markofová, Center Nr.: 42053
🇨🇿
Karlovy Vary, Czechia
Pavel Tománek, Center Nr.: 42028
🇨🇿
Kopivnice, Czechia
Jitka Hasalová, Center Nr.: 42010
🇨🇿
Kromiz, Czechia
AIDIN VK s.r.o., Center Nr.: 42017
🇨🇿
Perov, Czechia
árka Kubánková, Center Nr.: 42048
🇨🇿
Nymburk, Czechia
MUDr.Tomáš Edelsberger, Center Nr.: 42007
🇨🇿
Krnov, Czechia
MUDr. Eva Raická, Center Nr.: 42024
🇨🇿
Ostrava, Czechia
Barbora Diepoltová, Center Nr.: 42037
🇨🇿
Praha 9, Czechia
Siófoki Kórház Rendelintézet, Center Nr.: 36004
🇭🇺
Siófok, Hungary
Poradnia Diabetologiczna Dr. Adamczyk-Gajda, Center Nr.: 48031
🇵🇱
Olenica, Poland
Zakad Opieki Medycznej Sanatio; Sp. Z. o.o., Center Nr.: 48030
🇵🇱
Kraków, Poland
Orodek Praktyka Lekarska Konrad Strzelczyk, Center Nr.: 48012
🇵🇱
Woomin, Poland
National Medical Research Center for Endocrinology, Center Nr.: 70025
🇷🇺
Moskau, Russian Federation
Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70081
🇷🇺
Moskau, Russian Federation
Vessel Clinic, Center Nr.: 70011
🇷🇺
Moskau, Russian Federation
Anna Rancová, Center Nr.: 42025
🇨🇿
Olomouc, Czechia
Gabinet Diabetologiczno- Internistyczny Katarzyna Wasilewska, Center Nr.: 48011
🇵🇱
Biaystok, Poland
DIABET HELP s.r.o., Center Nr.: 42058
🇨🇿
Kralupy nad Vltavou, Czechia
Martina Košková, Center Nr.: 42047
🇨🇿
Mladá Boleslav, Czechia
Agentura Science Pro spol. s.r.o., Center Nr.: 42002
🇨🇿
Olomouc, Czechia
MHAT "Julia Verevska-Byala" EOOD, Center Nr.: 35903
🇧🇬
Byala, Bulgaria
MC Saint Elisaveta-Rakovski EOOD, Center Nr.: 35909
🇧🇬
Rakovski, Bulgaria
MBAL- Dobrich AD, Center Nr.: 35916
🇧🇬
Dobrich, Bulgaria
MHAT "Medline Clinic", Center Nr.: 35911
🇧🇬
Plovdiv, Bulgaria
Dr. T. K. Bacheva - ASMP-IP-E EOOD, Center Nr.: 35904
🇧🇬
Dupnitsa, Bulgaria
MC Kuchuk Parij OOD, Center Nr.: 35906
🇧🇬
Plovdiv, Bulgaria
MC "Vitaclinic" EOOD, Center Nr.: 35901
🇧🇬
Sofia, Bulgaria
Michal Brada, Center Nr.: 42001
🇨🇿
Beclav, Czechia
MC Kalimat EOOD, Center Nr.: 35914
🇧🇬
Sofia, Bulgaria
Practice Dr. Alice Sýkorová, Center Nr.: 42057
🇨🇿
Bilina, Czechia
Zaviatiová, Petra, Center Nr.: 42004
🇨🇿
Havíov, Czechia
EUC Klinika eské Budjovice, Center Nr.: 42052
🇨🇿
Eské Budjovice, Czechia
Dr. Kovaová, Center Nr.: 42069
🇨🇿
Beroun, Czechia
Barbara Buzová, Center Nr.: 42003
🇨🇿
Havíov, Czechia
Radana Syslová, Center Nr.: 42035
🇨🇿
Hlušovice, Czechia
MUDr. Alica Vesela, Center Nr.: 42030
🇨🇿
Broumov, Czechia
Lékaský dm Géko, Center Nr.: 42059
🇨🇿
Eské Budjovice, Czechia
Pavel Kasík, Center Nr.: 42046
🇨🇿
Hoovice, Czechia
Practice Dr. Petr Maule, Center Nr.: 42054
🇨🇿
Humpolec, Czechia
Mediab Jihlava s.r.o., Center Nr.: 42066
🇨🇿
Jihlava, Czechia
árka Drinková, Center Nr.: 42038
🇨🇿
Lede Nad Sázavou, Czechia
Dobromila Vykoupilová, Center Nr.: 42033
🇨🇿
Nmice Nad Hanou, Czechia
Karel Churavý, Center Nr.: 42005
🇨🇿
Nový Jiín, Czechia
Josef íný, Center Nr.: 42026
🇨🇿
Opava, Czechia
MUDr.Tomáš Hrdina, Center Nr.: 42015
🇨🇿
Opono, Czechia
Radka Nágelová, Center Nr.: 42020
🇨🇿
Ostrava Poruba, Czechia
Practice Dr. René Turínek, Center Nr.: 42034
🇨🇿
Ostrava, Czechia
Jitka Homolová, Center Nr.: 42012
🇨🇿
Ostrava, Czechia
Zdenk Jankovec, Center Nr.: 42044
🇨🇿
Plze, Czechia
Diabetologická a interní ambulance, Center Nr.: 42064
🇨🇿
Podbrady, Czechia
Practice Dr. Milena Peterková, Center Nr.: 42063
🇨🇿
Praha 2, Czechia
Markéta Hovorková, Center Nr.: 42042
🇨🇿
Praha 4, Czechia
Jií Jón, Center Nr.: 42045
🇨🇿
Praha 5, Czechia
Milan Fleka, Center Nr.: 42041
🇨🇿
Praha 5, Czechia
Jakub Hron, Center Nr.: 42043
🇨🇿
Praha 4, Czechia
Practice Dr. Lucie Kufová, Center Nr.: 42062
🇨🇿
Praha 5, Czechia
Practice Dr. Ida Reissová, Center Nr.: 42056
🇨🇿
Praha 6, Czechia
MUDr. Jana Houdová, Center Nr.: 42068
🇨🇿
Praha, Czechia
Practice Dr. Petronela Janeková, Center Nr.: 42065
🇨🇿
Rumburk, Czechia
MUDr. Vra Prýmková, Center Nr.: 42070
🇨🇿
Píbram, Czechia
Dana Fialkoviová, Center Nr.: 42040
🇨🇿
Strakonice, Czechia
Marek Frydrych, Center Nr.: 42008
🇨🇿
Tebí, Czechia
Practice Dr. Miroslav Lindovský, Center Nr.: 42051
🇨🇿
Sokolov, Czechia
Marek Frydrych, Center Nr.: 42077
🇨🇿
Tebí, Czechia
Diabetologická ambulance s.r.o., Center Nr.: 42076
🇨🇿
Uherské Hradišt, Czechia
Lubomír Kudlej, Center Nr.: 42050
🇨🇿
Vrchlabí, Czechia
AdiaMed s.r.o., Center Nr.: 42009
🇨🇿
Vsetín, Czechia
Robin Urbánek, Center Nr.: 42029
🇨🇿
Zlín, Czechia
Bajcsy-Zsilinszky Kórház és Rendelintézet, Center Nr.: 36019
🇭🇺
Budapest, Hungary
Jahn Ferenc Dél-pesti Kórház és Rendelintézet, Center Nr.: 36014
🇭🇺
Budapest, Hungary
Debreceni Egyetem Klinikai Központ, Kardiológiai Klinika, Center Nr.: 36006
🇭🇺
Debrecen, Hungary
Kátai Gábor Kórház, Diabetológia Szakrendelés, Center Nr.: 36007
🇭🇺
Karcag, Hungary
Nagyatádi Kórház, Center Nr.: 36021
🇭🇺
Nagyatád, Hungary
Nyírségi Diabetes Centrum, Center Nr.: 36024
🇭🇺
Nyíregyháza, Hungary
Dr. Wagner Zoltán, Center Nr.: 36020
🇭🇺
Pécs, Hungary
Soproni Gyógyközpont, Center Nr.: 36018
🇭🇺
Sopron, Hungary
Prywatny Gabinet Lekarski dr n. med. Joanna Sawer-Szewczyk, Center Nr.: 48055
🇵🇱
Czyca, Poland
NZOZ DIAMED Sp. z o.o., Center Nr.: 48061
🇵🇱
Czechowice-Dziedzice, Poland
Zespó Opieki Zdrowotnej w czycy, Center Nr.: 48054
🇵🇱
Czyca, Poland
Poradnia Diabetologiczna, Center Nr.: 48028
🇵🇱
Gorlice, Poland
NZOZ Sal Med, Center Nr.: 48047
🇵🇱
Dzieroniów, Poland
NZOZ Poradnia Diabetologiczna, Center Nr.: 48038
🇵🇱
Konin, Poland
Indywidualna Specjalistyczna Praktyka Lekarska Wiesawa Fischer, Center Nr.: 48020
🇵🇱
Ostrów Wielkopolski, Poland
Anturium, Center Nr.: 70036
🇷🇺
Barnaul, Russian Federation
Limited Liability Company "Uralsky Medical Center", Center Nr.: 70063
🇷🇺
Ekaterinburg, Russian Federation
City Polyclinic No. 16, Center Nr.: 70067
🇷🇺
Khabarovsk, Russian Federation
City Polyclinic No 107 of the Moscow City Healthcare Department, Center Nr.: 70082
🇷🇺
Moscow, Russian Federation
Privolzhsky Research Medical University, Center Nr.: 70085
🇷🇺
Nizhny Novgorod, Russian Federation
City clinical hospital #12 of Sormovskiy district of Nizhniy Novgorod, Center Nr.: 70018
🇷🇺
Nizhniy Novgorod, Russian Federation
AVICENNA, Center Nr.: 70064
🇷🇺
Novosibirsk, Russian Federation
North-West State Medical University named after II. Mechnikov, Center Nr.: 70053
🇷🇺
Saint Petersbug, Russian Federation
City polyclinic #16 of the City Rostov-on-Don, Center Nr.: 70027
🇷🇺
Rostov-on-Don, Russian Federation
North-West State Medical University named after II. Mechnikov, Center Nr.: 70077
🇷🇺
Saint Petersbug, Russian Federation
Medilux-TM, Center Nr.: 70005
🇷🇺
Saint Petersburg, Russian Federation
First Saint-Petersburg state medical university named after acad. I.P.Pavlov, Center Nr.: 70024
🇷🇺
Saint-Petersburg, Russian Federation
City Pokrovskaya Hospital, Center Nr.: 70022
🇷🇺
Saint Petersburg, Russian Federation
Samara city polyclinic Nr. 9 of Oktyabrskiy district, Center Nr.: 70028
🇷🇺
Samara, Russian Federation
Clinical Hospital of the Saratov city, Center Nr.: 70090
🇷🇺
Saratov, Russian Federation
Samara city consulting and diagnostic polyclinic nr. 14, Center Nr.: 70029
🇷🇺
Samara, Russian Federation
Multifunctional Medical Clinic "Sova", Center Nr.: 70030
🇷🇺
Saratov, Russian Federation
V.A. Almazov National Medical Research Center, Center Nr.: 70071
🇷🇺
St. Petersburg, Russian Federation
AntMed, Center Nr.: 70034
🇷🇺
St. Petersburg, Russian Federation
Dr. Tsiberkin, Center Nr.: 70048
🇷🇺
St. Petersburg, Russian Federation
Regional Endocrinological Dispensary, Center Nr.: 70078
🇷🇺
Stavropol, Russian Federation
Tyumen State Medical University, Center Nr.: 70066
🇷🇺
Tyumen, Russian Federation
Limited Liability Company "CENTER", Center Nr.: 70060
🇷🇺
Vladivostok, Russian Federation
Regional Clinical Hospital No. 2, Center Nr.: 70092
🇷🇺
Vladivostok, Russian Federation
Voronezh City Clinical Hospital #11, Center Nr.: 70035
🇷🇺
Voronezh, Russian Federation
State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70017
🇷🇺
Voronezh, Russian Federation
Clinical Polyclinic No.28, Center Nr.: 70040
🇷🇺
Volgograd, Russian Federation
State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70055
🇷🇺
Voronezh, Russian Federation
State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70033
🇷🇺
Voronezh, Russian Federation
Dr. Šeptáková, Center Nr.: 42074
🇨🇿
Ostrava, Czechia
Dr. Hrmová, Center Nr.: 42073
🇨🇿
Vlašim, Czechia
Acibadem City Clinic Medical Center Varna EOOD, Center Nr.: 35908
🇧🇬
Varna, Bulgaria
EUC Klinika Zlín a.s., Center Nr.: 42075
🇨🇿
Zlín, Czechia
City Polyclinic No. 22 of the Department of Healthcare of the Moscow City, Center Nr.: 70043
🇷🇺
Moscow, Russian Federation
City Polyclinic No. 22 of the Department of Healthcare of the Moscow City, Center Nr.: 70045
🇷🇺
Moscow, Russian Federation
Practice Dr. Lelkesi Anita, Center Nr.: 36013
🇭🇺
Mátészalka, Hungary
Indywidualna Specjalistyczna Praktyka Lekarska Piotr Piskozub Specjalista Diabetolog, Center Nr.: 48042
🇵🇱
Jelenia Góra, Poland
Prywatny Gabinet Lekarski Tomasz Wierzykowski, Center Nr.: 48053
🇵🇱
Kutno, Poland
Indywidualna Specjalistyczna Praktyka Lekarska Magorzata Poskoska-Lemaska, Center Nr.: 48035
🇵🇱
Kwidzyn, Poland
Indywidualna Specjalistyczna Praktyka Lekarska Barbara Soróbka, Center Nr.: 48001
🇵🇱
Legnica, Poland
Chelyabinsk regional clinical hospital, Center Nr.: 70069
🇷🇺
Chelyabinsk, Russian Federation
Scientific and Practical Center of Specialized Types of Medical Care "Uralskij Institute of Cardiology", Center Nr.: 70079
🇷🇺
Ekaterinburg, Russian Federation
Russian Medical Academy of Continuing Professional Education, Center Nr.: 70058
🇷🇺
Irkutsk, Russian Federation
The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic, Center Nr.: 70037
🇷🇺
Izhevsk, Russian Federation
Central City Hospital No. 18, Center Nr.: 70051
🇷🇺
Kazan, Russian Federation
Kemerovo regional clinical hospital named S.V. Belyaev, Center Nr.: 70008
🇷🇺
Kemerovo, Russian Federation
Kirov Clinical Hospital No. 7 named after V.I. Yurlova, Center Nr.: 70089
🇷🇺
Kirov, Russian Federation
Lipetsk Regional Hospital, Center Nr.: 70046
🇷🇺
Lipetsk, Russian Federation
Krai clinical hospital Nr. 1 named after prof. S.V. Ochapovskogo, Center Nr.: 70049
🇷🇺
Krasnodar, Russian Federation
Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70084
🇷🇺
Moskau, Russian Federation
City Clinical Hospital named after V.V. Veresaeva of the Moscow Department of Health, Center Nr.: 70003
🇷🇺
Moskau, Russian Federation
City Polyclinic No. 1, Center Nr.: 70074
🇷🇺
Nalchik, Russian Federation
Novokuznetsk City Clinical Hospital No. 1, Center Nr.: 70050
🇷🇺
Novokuznetsk, Russian Federation
AVICENNA, Center Nr.: 70065
🇷🇺
Novosibirsk, Russian Federation
City Clinical Polyclinic #16, Center Nr.: 70056
🇷🇺
Novosibirsk, Russian Federation
City clinical hospital 5, Center Nr.: 70057
🇷🇺
Perm, Russian Federation
City clinical hospital 5, Center Nr.: 70070
🇷🇺
Perm, Russian Federation
Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70032
🇷🇺
Moskau, Russian Federation
Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70041
🇷🇺
Moskau, Russian Federation
Novosibirsk State Medical University, Center Nr.: 70059
🇷🇺
Novosibirsk, Russian Federation
Private Clinic Salon Roden, Center Nr.: 70086
🇷🇺
Perm, Russian Federation
First Saint-Petersburg state medical university named after acad. I.P.Pavlov, Center Nr.: 70087
🇷🇺
Saint-Petersburg, Russian Federation
LLC clinic "Family Doctor", Center Nr.: 70093
🇷🇺
Saratov, Russian Federation
Zabotlivyi Doktor, Center Nr.: 70016
🇷🇺
St. Petersburg, Russian Federation
Volgograd Regional Clinical Hospital No. 3, Center Nr.: 70076
🇷🇺
Volgograd, Russian Federation
City clinical hospital, Center Nr.: 70019
🇷🇺
Ufa, Russian Federation
City Polyclinic No.2, Center Nr.: 70062
🇷🇺
Ulan-Ude, Russian Federation
Regional Clinical Hospital No. 2, Center Nr.: 70068
🇷🇺
Vladivostok, Russian Federation
SBIH Center for Speech Pathology and Neurorehabilitation MDH, Center Nr.: 70080
🇷🇺
Moscow, Russian Federation
Clinical Hospital No. 85 of trhe Federal Biomedical Agency, Center Nr.: 70042
🇷🇺
Moscow, Russian Federation